AC Immune Targeting $50m IPO
Executive Summary
Alzheimer's disease drug and vaccine developer AC Immune SA is aiming to raise $50m via an initial public offering that will take the company public on Nasdaq in the US. This follows a successful series E financing round in May this year that saw the company net $43.5m.
You may also be interested in...
IPO Update: Novan, AC Immune End Summer Slowdown As Market Improves
Novan and AC Immune ended September with the first biopharma IPOs in 40 days as the performance of newly public companies’ stocks head into an upswing.
IPO Update: Haircuts Needed To Price Biotech Offerings
The two drug developers that managed to launch initial public offerings in the US during the past two weeks had to accept rough haircuts in order to get investors to buy their newly issued stock.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.